Kanjinti 150 mg (Trastuzumab POWDER FOR SOLUTION) 150 MG

KANJINTI 150 MG is a powder for solution used in intravenous therapy. It contains trastuzumab, a monoclonal antibody indicated for certain types of cancer. This medication is manufactured by Amgen Canada Inc.

Strength

150 MG

Manufacturer / TM Owner

AMGEN CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

KANJINTI 150 MG is primarily used in the treatment of specific types of cancer, particularly those that involve the HER2 protein. It is often prescribed for breast cancer and gastric cancer that overexpress this protein. The medication works by targeting and blocking the growth of cancer cells, helping to slow or stop their progression. Patients should consult their healthcare provider to determine if KANJINTI is suitable for their condition.

Side Effects

Common effects of KANJINTI 150 MG may include fatigue, nausea, and fever. Some patients might experience pain at the injection site or a general feeling of weakness. Severe side effects are rare but can occur, and patients should report any unusual symptoms to their healthcare provider immediately.

Precautions & Warnings

KANJINTI 150 MG should be handled with care and administered by a healthcare professional. It is important to follow the prescribed dosage and administration instructions closely. Patients with a history of heart problems should discuss this with their doctor before starting treatment. Always store the medication as directed to maintain its efficacy.

Avoid Interactions

KANJINTI 150 MG may interact with other medications, particularly those that affect the immune system or heart function. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol and certain foods may also interact with KANJINTI, so patients should follow their doctor's advice regarding lifestyle modifications.

Frequently Asked Questions

KANJINTI 150 MG is used in the treatment of certain types of cancer, particularly those involving the HER2 protein, such as breast cancer and gastric cancer.

KANJINTI 150 MG is administered intravenously as a solution prepared from the powder.

Common side effects may include fatigue, nausea, fever, and pain at the injection site.

Patients should consult their healthcare provider before combining KANJINTI 150 MG with other medications, as interactions may occur.

KANJINTI 150 MG is manufactured by Amgen Canada Inc.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.